Pristanic acid-d₃

Cat. No.: HY-113024S: FAQs
Data Sheet Handling Instructions

Molarity Calculator

Pristanic acid-d₃ is deuterium labeled Pristanic acid. Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome.

For research use only. We do not sell to patients.

Pristanic acid-</sub>d<sub>3</sub> Chemical Structure

Pristanic acid-d₃ Chemical Structure

CAS No. : 1383920-14-6

Size		Stock
MOQ		Minimum order quantity
50 mg		Get quote
100 mg		Get quote
250 mg		Get quote
Other size		Get quote

Synthetic products have potential research and development risk.

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description	Pristanic acid-d₃ is deuterium labeled Pristanic acid. Pristanic acid is an endogenous metabolite present in Blood that can be used for the research of Alpha Methylacyl CoA Racemase Deficiency and Zellweger Syndrome^[1]^[2]^[3]^[1]^[2]^[3]^[4].
Molecular Weight	301.52
Formula	C₁₉H₃₅D₃O₂
CAS No.	1383920-14-6
Unlabeled CAS	1189-37-3
SMILES	OC(C(C([2H])([2H])[2H])CCCC(C)CCCC(C)CCCC(C)C)=O
Shipping	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation	Data Sheet (262 KB) Handling Instructions (2659 KB)
References	[1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief] [2]. McLean BN, et al. A new defect of peroxisomal function involving pristanic acid: a case report. J Neurol Neurosurg Psychiatry. 2002 Mar;72(3):396-9. [Content Brief] [3]. Baumgartner MR, et al. Clinical approach to inherited peroxisomal disorders: a series of 27 patients. Ann Neurol. 1998 Nov;44(5):720-30. [Content Brief] [4]. Lee N, et al. Endogenous toxic metabolites and implications in cancer therapy. Oncogene. 2020 Aug;39(35):5709-5720. [Content Brief]